Zanubrutinib

( DrugBank: Zanubrutinib / KEGG DRUG: Zanubrutinib )


5 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis1
63Idiopathic thrombocytopenic purpura4
222Primary nephrotic syndrome1
IDDisease name (Link within this page)Number of trials
300IgG4-related disease1
331Idiopathic multicentric castleman disease1

13. Multiple sclerosis


Clinical trials : 3,685Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

63. Idiopathic thrombocytopenic purpura


Clinical trials : 575Drugs : 261 - (DrugBank : 64) / Drug target genes : 61 - Drug target pathways : 142 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

222. Primary nephrotic syndrome


Clinical trials : 382Drugs : 278 - (DrugBank : 98) / Drug target genes : 73 - Drug target pathways : 197 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

300. IgG4-related disease


Clinical trials : 57Drugs : 52 - (DrugBank : 29) / Drug target genes : 20 - Drug target pathways : 147 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

331. Idiopathic multicentric castleman disease


Clinical trials : 40Drugs : 45 - (DrugBank : 29) / Drug target genes : 43 - Drug target pathways : 163 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries